[Latest] Global Hydrogen Generation Market Size/Share Worth USD 280.4 Billion by 2032 at a 8.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
27 févr. 2024 14h30 HE
|
Custom Market Insights
Austin, TX, USA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hydrogen Generation Market Size, Trends and Insights By Source (Green Hydrogen,...
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – IMRA, SAL, APEN, GRAY
28 déc. 2022 15h41 HE
|
Monteverde & Associates PC
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SAL, VVNT, APEN, GRAY
14 déc. 2022 16h00 HE
|
Monteverde & Associates PC
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Acquisition – GRAY, APEN, SAL, KNBE
07 déc. 2022 16h27 HE
|
Monteverde & Associates PC
NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022
10 nov. 2022 16h59 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on...
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments
11 août 2022 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today...
Graybug to Present at the 2022 OIS Retina Innovation Summit
06 juil. 2022 07h15 HE
|
Graybug Vision, Inc.
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Announces Review of Strategic Alternatives
28 juin 2022 07h15 HE
|
Graybug Vision, Inc.
BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting
19 mai 2022 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...
Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments
10 mai 2022 16h05 HE
|
Graybug Vision, Inc.
BALTIMORE, May 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today...